Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q2 FY21 results · Jul–Sep 2020
Solara Active Pharma Sciences reported revenue from operations of ₹397.56 crore (up 13.2% from Q2 FY20) and net profit of ₹56.69 crore (up 96.3% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 397.56 | 351.13 | +13.2% | 348.42 | +14.1% |
| Other income | 6.12 | 4.95 | +23.6% | 4.58 | +33.6% |
| Total income | 403.68 | 356.08 | +13.4% | 353.00 | +14.4% |
| Profit before tax | 56.77 | 29.18 | +94.6% | 42.32 | +34.1% |
| Net profit for the period | 56.69 | 28.88 | +96.3% | 42.27 | +34.1% |
| EPS, basic (₹) | 19.21 | 11.21 | not comparable | 15.74 | not comparable |
| Net margin (%) | 14.3 | 8.2 | 12.1 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 397.56 | 350.36 | +13.5% | 348.42 | +14.1% |
| Other income | 5.68 | 4.41 | +28.8% | 4.58 | +24.0% |
| Total income | 403.24 | 354.77 | +13.7% | 353.00 | +14.2% |
| Profit before tax | 55.94 | 36.79 | +52.1% | 42.09 | +32.9% |
| Net profit for the period | 55.94 | 36.79 | +52.1% | 42.09 | +32.9% |
| EPS, basic (₹) | 18.97 | 14.27 | not comparable | 15.67 | not comparable |
| Net margin (%) | 14.1 | 10.5 | 12.1 |
Consolidated
- Filed with BSE
- 04 Nov 2020, 15:22 IST
- Board meeting
- 30 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Nov 2020, 15:22 IST
- Board meeting
- 30 Oct 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE